The short version of c-Met signaling fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-02. Anything still debated is marked as such rather than presented as settled.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
== Mechanism of action == As studied mainly on cisplatin, but presumably for other members as well, platinum-based antineoplastic agents cause crosslinking of DNA as monoadduct, interstrand crosslinks, intrastrand crosslinks or DNA protein crosslinks. Mostly they act on the adjacent N-7 position of guanine, forming a 1, 2 intrastrand crosslink. The resultant crosslinking inhibits DNA repair and/or DNA synthesis. This mechanism leads to specific patterns of damage in DNA, which can kill cancer cells but can also increase the risk of secondary tumors developing. Platinum(IV) prodrugs have also been investigated as a strategy to overcome resistance to platinum chemotherapy. In preclinical models of prostate cancer, the cisplatin prodrug Platin-L inhibited fatty acid oxidation through interaction with CPT1A and showed activity against cisplatin-resistant tumors. Platinum-based antineoplastic agents are sometimes described as "alkylating-like" due to similar effects as alkylating antineoplastic agents, although they do not have an alkyl group.
== Synthesis == The first reported syntheses of fluoroalanine in 1976 involved treating cysteine with difluorine under an inert atmosphere. This produced a mixture of 3-fluoroalanine and 3,3-difluoroalanine, with the former as the major component.
costmary, 1–66 grams sweet flag, 20 grams hypericum, 8 grams Natural gum, 8 grams sagapenum, 8 grams acacia juice, 8 grams Illyrian iris (probably I. germanica), 8 grams cardamom, 8 grams anise, 12 grams Gallic nard (Valeriana italica), 16 grams gentian root, 16 grams dried rose leaves, 16 grams poppy-tears (Papaver rhoeas, a wild poppy with low opiate content), 17 grams parsley, 17 grams cassia, 20–66 grams saxifrage, 20–66 grams darnel, 20–66 grams long pepper, 20–66 grams storax, 21 grams castoreum, 24 grams frankincense, 24 grams hypocistis juice, 24 grams myrrh, 24 grams opopanax, 24 grams malabathrum leaves, 24 grams flower of round rush, 24–66 grams turpentine-resin, 24–66 grams galbanum, 24–66 grams Cretan carrot seeds, 24–66 grams nard, 25 grams opobalsam, 25 grams shepherd's purse, 25 grams rhubarb root, 28 grams saffron, 29 grams ginger, 29 grams cinnamon, 29 grams The ingredients are then "pounded and taken up in honey. Against poisoning, a piece the size of an almond is given in wine. In other affections an amount corresponding in size to an Egyptian bean is sufficient." Of these ingredients, Illyrian iris, darnel, and rhubarb were not commonly found in other versions of the antidote. However, Celsus' formulation, written 100 years after the death of Mithridates, was one of the first published. Galen called the antidote "theriac" and presented versions by Aelius (used by Julius Caesar), Andromachus (physician to Nero), Antipater, Nicostratus, and Damocratis. The Andromachus formulation closely resembles that of Celsus.
=== Herpes zoster === Herpes zoster (shingles) most often occurs in the elderly and is only rarely seen in children. The incidence of herpes zoster in vaccinated adults is 0.9/1000 person-years, and is 0.33/1000 person-years in vaccinated children; this is lower than the overall incidence of 3.2–4.2/1000 person-years. The risk of developing shingles is reduced for children who receive the varicella vaccine, but not eliminated. The CDC stated in 2014: "Chickenpox vaccines contain weakened live VZV, which may cause latent (dormant) infection. The vaccine-strain VZV can reactivate later in life and cause shingles. However, the risk of getting shingles from vaccine-strain VZV after chickenpox vaccination is much lower than getting shingles after natural infection with wild-type VZV." The risk of shingles is significantly lower among children who have received varicella vaccination, including those who are immunocompromised. The risk of shingles is approximately 80% lower among healthy vaccinated children compared to unvaccinated children who had wild-type varicella. A population with high varicella vaccination also has lower incidence of shingles in unvaccinated children, due to herd immunity.
== Methods for determining catalase activity == In 1870, Schoenn discovered a formation of yellow color from the interaction of hydrogen peroxide with molybdate; then, from the middle of the 20th century, this reaction began to be used for colorimetric determination of unreacted hydrogen peroxide in the catalase activity assay. The reaction became widely used after publications by Korolyuk et al. (1988) and Goth (1991). The first paper describes serum catalase assay with no buffer in the reaction medium; the latter describes the procedure based on phosphate buffer as a reaction medium. Since phosphate ion reacts with ammonium molybdate, the use of MOPS buffer as a reaction medium is more appropriate. Direct UV measurement of the decrease in the concentration of hydrogen peroxide is also widely used after the publications by Beers & Sizer and Aebi.
Sources: en.wikipedia.org
Adanson (1763), de Jussieu (1789), and Candolle (1819) all proposed various alternative natural systems of classification that grouped plants using a wider range of shared characters and were widely followed. The Candollean system reflected his ideas of the progression of morphological complexity and the later Bentham & Hooker system, which was influential until the mid-19th century, was influenced by Candolle's approach. Darwin's publication of the Origin of Species in 1859 and his concept of common descent required modifications to the Candollean system to reflect evolutionary relationships as distinct from mere morphological similarity. In the 19th century botany was a socially acceptable hobby for upper-class women. These women would collect and paint flowers and plants from around the world with scientific accuracy. The paintings were used to record many species that could not be transported or maintained in other environments. Marianne North illustrated over 900 species in extreme detail with watercolour and oil paintings. Her work and many other women's botany work was the beginning of popularising botany to a wider audience. Botany was greatly stimulated by the appearance of the first "modern" textbook, Matthias Schleiden's Grundzüge der Wissenschaftlichen Botanik, published in English in 1849 as Principles of Scientific Botany.
== AFL career == Steinberg was selected by Essendon with the thirty-first pick in the 2010 AFL draft in November 2010. Ariel was drafted from the Bendigo Pioneers in the TAC Cup having joined the Pioneers squad halfway through the 2010 season. He started playing for the Bendigo Bombers in their 2011 season. He kicked 3 goals against Frankston on 17 April 2011. He kicked 5 goals against the Box Hill Hawks on 19 June 2011. He kicked four goals against the Werribee Tigers on 7 August 2011. He kicked three goals against the Northern Bullants on 4 September 2011. He scored 25 goals in 2011. He was delisted in October 2015. Steinberg, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his teammates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for two years which, with backdating, ended in November 2016; as a result, he served approximately fourteen months of his suspension and missed the entire 2016 VFL season, during which time he had intended to play for VFL club Williamstown.
== Drug targets == A biomolecular target (most commonly a protein or a nucleic acid) is a key molecule involved in a particular metabolic or signaling pathway that is associated with a specific disease condition or pathology or to the infectivity or survival of a microbial pathogen. Potential drug targets are not necessarily disease causing but must by definition be disease modifying. In some cases, small molecules will be designed to enhance or inhibit the target function in the specific disease modifying pathway. Small molecules (for example receptor agonists, antagonists, inverse agonists, or modulators; enzyme activators or inhibitors; or ion channel openers or blockers) will be designed that are complementary to the binding site of target. Small molecules (drugs) can be designed so as not to affect any other important "off-target" molecules (often referred to as antitargets) since drug interactions with off-target molecules may lead to undesirable side effects. Due to similarities in binding sites, closely related targets identified through sequence homology have the highest chance of cross reactivity and hence highest side effect potential. Most commonly, drugs are organic small molecules produced through chemical synthesis, but biopolymer-based drugs (also known as biopharmaceuticals) produced through biological processes are becoming increasingly more common. In addition, mRNA-based gene silencing technologies may have therapeutic applications.
==== Deformation metamorphic reactions ==== Deformation events may trigger metamorphic reactions which produce monazite. For example, a metamorphic reaction associated with the movement in the Legs Lake shear zone partly replaced garnet with cordierite. This reaction also generated new monazite with high content of Y, and dated around 1850 Ma. The age is interpreted as the timing of shearing. Monazite-forming reactions may happen a bit later than shearing after the rocks have been in re-equilibrium in response to a new pressure environment. That means monazite age may not be closely equivalent to shearing age, but it provides a more precise age than other methods.
Sources: en.wikipedia.org
=== Names === Enobosarm is the generic name of the drug and its International Nonproprietary Name (INN). Ostarine was a tentative brand name of the drug created by GTx, Inc. that did not end up being used for marketing purposes but continues to be used as a synonym for the drug. Enobosarm is also known by the pharmaceutical developmental code names S-22 (synthesis paper), GTx-024 (GTx, Inc.), MK-2866 (Merck), and VERU-024 (Veru, Inc.).
=== Toxicity === Iron is also potentially toxic. Its ability to donate and accept electrons means that it can catalyze the conversion of hydrogen peroxide into free radicals. Free radicals can cause damage to a wide variety of cellular structures, and ultimately kill the cell. Iron bound to proteins or cofactors such as heme is safe. Also, there are virtually no truly free iron ions in the cell, since they readily form complexes with organic molecules. However, some of the intracellular iron is bound to low-affinity complexes, and is termed labile iron or "free" iron. Iron in such complexes can cause damage as described above. To prevent that kind of damage, all life forms that use iron bind the iron atoms to proteins. This binding allows cells to benefit from iron while also limiting its ability to do harm. Typical intracellular labile iron concentrations in bacteria are 10–20 micromolar, though they can be 10-fold higher in anaerobic environment, where free radicals and reactive oxygen species are scarcer. In mammalian cells, intracellular labile iron concentrations are typically smaller than 1 micromolar, less than 5 percent of total cellular iron.
Having lost the race to the Moon, the USSR seemed to decide to concentrate on orbital space stations instead of pursuing a crewed lunar mission. During 1969 and 1970, they launched six more Soyuz flights after Soyuz 3 and then launched a series of six successful space stations (plus two failures to achieve orbit and one station rendered uninhabitable due to damage from explosion of the launcher's upper stage) on their Proton-K heavy-lift launcher in their Salyut program designed by Kerim Kerimov. Each one weighed between 18,500 and 19,824 kilograms (40,786 and 43,704 lb), was 20 meters (66 ft) long by 4 meters (13 ft) in diameter, and had a habitable volume of 99 cubic meters (3,500 ft3). All of the Salyuts were presented to the public as non-military scientific laboratories, but three of them were covers for military Almaz reconnaissance stations: Salyut 2 (failed), Salyut 3, and Salyut 5.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.